A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes

Trial Profile

A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Saxagliptin (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SAVOR; SAVOR-TIMI-53
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 17 Oct 2016 Results of predefined exploratory end points of renal safety and efficacy and analyses of the albumin/creatinine ratio change over time published in the Diabetes Care
    • 19 May 2016 Results of a retrospective analysis on Cardiovascular Outcomes of EMPA-REG, PROactive, ORIGIN, SAVOR, EXAMINE, CANVAS, ELIXA, TECOS, LEADER studies, published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top